# Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL

> **NCT03524235** · PHASE1 · COMPLETED · sponsor: **Noah Merin** · enrollment: 20 (actual)

## Conditions studied

- Multiple Myeloma
- CLL
- Chronic Lymphocytic Leukemia
- Lymphoma
- Hodgkin Lymphoma

## Interventions

- **RADIATION:** Total Body Irradiation
- **PROCEDURE:** Haploidentical Stem Cell Transplantation
- **BIOLOGICAL:** CD56-Enriched Donor Lymphocyte Infusion
- **DRUG:** Bendamustine
- **DRUG:** Fludarabine
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03524235
- **Lead sponsor:** Noah Merin
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-18
- **Primary completion:** 2021-11-07
- **Final completion:** 2024-11-06
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2024-11-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03524235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03524235, "Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03524235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*